Induction of uterine adenomyosis by pituitary grafting and retardation of its development by bromocriptine-mesilate (CB-154) in BALB/c mice

Taketoshi Mori, T Mori, Mori T, Kawashima S, S Kawashima, Nagasawa H, H. Nagasawa
In vivo (Athens, Greece) · 1992 · vol. 5(2) , pp. 107–9 · PMID:1768777 · W2399593713
Lab / animal OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Pituitary grafting induced adenomyosis in mice, and bromocriptine treatment during youth suppressed its development.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Development of uterine adenomyosis was examined in BALB/c mice. Anterior pituitary (AP) isografting at 8 weeks of age significantly increased the incidence of adenomyosis in mice by 36 weeks of age as compared to that in control mice bearing no AP isograft. However, in mice with AP grafting, daily administration of 0.2 mg bromocriptine-mesilate (CB-154) between 4 and 8 weeks of age decreased the incidence of adenomyosis at 36 weeks of age to the level of control mice. These results suggest that in mice AP grafting stimulates the development of adenomyosis and that pretreatment with CB-154 during youth can suppress the development.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenoma Bromocriptine Pituitary Gland, Anterior Uterine Neoplasms Adenoma Adenoma Adenoma Animals Animals Body Weight Body Weight Bromocriptine Bromocriptine Female Female Mice Mice Mice, Inbred BALB C Mice, Inbred BALB C Organ Size

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (6)

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:04:39.942088+00:00
License: CC0 · commercial use OK